Corticotropin-releasing factor testing reveals a dose-dependent difference in methadone maintained vs control subjects

Neuropsychopharmacology

Volumn 28, Issue 5, 2003, Pages 985-994

  Schluger, James H ^a   Bart, Gavin ^a   Green, Mark ^a   Ho, Ann ^a   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

ACTH; Addiction; Corticotropin releasing factor (CRF); Cortisol; HPA axis; Methadone

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; HYDROCORTISONE; METHADONE;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; HEROIN DEPENDENCE; HUMAN; MALE; MIDDLE AGED;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CORTICOTROPIN-RELEASING HORMONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEROIN DEPENDENCE; HUMANS; HYDROCORTISONE; MALE; METHADONE; MIDDLE AGED;

EID: 0038727251     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300156     Document Type: Article

References (90)

1. Avgerinos PC, Schurmeyer TH, Gold PW, Tomai TP, Loriaux DL, Sherins RJ et al (1986). Pulsatile administration of human corticotropin-releasing hormone in patients with secondary adrenal insufficiency: restoration of the normal cortisol secre-tory pattern. J ClinEndocrinolMetab 62: 816-821.
2. Bale TL, Picetti R, Contarino A, Koob GF, Vale WW, Lee KF (2002). Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J Neurosci 22: 193-199.
3. Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M et al (1997). Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry 2: 490-494.
4. Berrettini WH, Hoehe MR, Ferraro TN, DeMaria PA, Gottheil E (1997). Human mu opioid receptor gene polymorphisms and vulnerability to substance abuse. Addict Biol 2: 303-308.
5. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L et al (1998). Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. ProcNatlAcadSci USA 95: 9608-9613.
6. Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM et al (1997). Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 154: 624-629.
7. Buckingham JC (1982). Secretion of corticotrophin and its hypothalamic releasing factor in response to morphine and opioid peptides. Neuroendocrinology 35: 111-116.
8. Buckingham JC, Cooper TA (1984). Differences in hypothalamo-pituitary-adrenocortical activity in the rat after acute and prolonged treatment with morphine. Neuroendocrinology 38: 411-417.
9. Chen ACH, LaForge KS, Ho A, McHugh PF, Kellogg S, Bell K et al (2002). A potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am J Med Genet 114: 429-435.
10. Coplan JD, Andrews MW, Rosenblum LA, Owens MJ, Friedman S, Gorman JM et al (1996). Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc NatlAcadSci USA 93: 1619-1623.
11. Curtis GC, Abelson JL, Gold PW (1997). Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. Biol Psychiatry 41: 76-85.
12. Cushman Jr P, Kreek MJ (1974). Some endocrinologicobserva-tions in narcotic addicts. In: Zimmermann E, George R (eds). Narcotics and the Hypothalamus. Raven Press: New York. pp 161-173.
13. De Souza EB, Whitehouse PJ, Price DL, Vale WW (1987). Abnormalities in corticotropin-releasing hormone (CRH) in Alzheimer’s disease and other human disorders. Ann NY Acad Sci 512: 237-247.
14. Dole VP, Nyswander ME, Kreek MJ (1966). Narcotic blockade. Arch Intern Med 118: 304-309.
15. Dole VP, Kreek MJ (1973). Methadone plasma level: sustained by a reservoir of drug in tissue. ProcNatlAcadSci USA 70: 10.
16. Ehlers CL, Henriksen SJ, Wang M, Rivier J, Vale W, Bloom FE (1983). Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats. Brain Res 278: 332-336.
17. Eisenman AJ, Fraser HF, Brooks JW (1961). Urinary excretion and plasma levels of 17-hydroxycorticosteroids during a cycle of addiction to morphine. J ClinEndocrinolMetab 132: 226-231.
18. Eisenman AJ, Fraser HF, Sloan J, Isbell H (1958). Urinary 17-ketosteroid excretion during a cycle of addiction to morphine. J ClinEndocrinolMetab 124: 305-311.
19. Eisenman AJ, Sloan JW, Martin WR, Jasinski DR, Brooks JW (1969).Catecholamine and 17-hydroxycorticosteroid excretion during a cycle of morphine dependence in man. J Psychiatr Res 7: 19-28.
20. Erb S, Shaham Y, Stewart J (1998). The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats. J Neurosci 18: 5529-5536.
21. Franke P, Wang T, Nothen MM, Knapp M, Neidt H, Albrecht S et al (2001). Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence. Am J Med Genet105: 114-119.
22. Gelernter J, Kranzler H, Cubells J (1999). Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: popula-tion studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry 4: 476-483.
23. Gianoulakis C, Krishnan B, Thavundayil J (1996). Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry 53: 250-257.
24. Goeders NE, Guerin GF (1996). Effects of surgical and pharmaco-logical adrenalectomy on the initiation and maintenance of intravenous cocaine self-administration in rats. Brain Res 722: 145-152.
25. Goeders NE, Peltier RL, Guerin GF (1998). Ketoconazole reduces low dose cocaine self-administration in rats. Drug Alcohol Depend 53: 67-77.
26. Heinrichs SC, Menzaghi F, Schulteis G, Koob GF, Stinus L (1995). Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. BehavPharmacol 6: 74-80.
27. Hundt W, Zimmermann U, Pottig M, Spring K, Holsboer F (2001). The combined dexamethasone-suppression/CRH-stimulation test in alcoholics during and after acute withdrawal. Alcohol ClinExp Res 25: 687-691.
28. Ignar DM, Kuhn CM (1990). Effects of specific mu and kappa opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat. J PharmacolExpTher 255: 1287-1295.
29. Inturrisi CE, Verebely K (1972). The levels of methadone in the plasma in methadone maintenance. ClinPharmacolTher 13: 633-637.
30. Kennedy JA, Hartman N, Sbriglio R, Khuri E, Kreek MJ (1990). Metyrapone-induced withdrawal symptoms. Br J Addict 85: 1133-1140.
31. Kling MA, Carson RE, Borg L, Zametkin A, Matochik JA, Schluger J et al (2000). Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J PharmacolExpTher 295: 1070-1076.
32. Koob GF (1999). Stress, corticotropin-releasing factor, and drug addiction. Ann NY AcadSci 897: 27-45.
33. Kosten TR, Kreek MJ, Ragunath J, Kleber HD (1986a). A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. Life Sci 39: 55-59.
34. Kosten TR, Kreek MJ, Ragunath J, Kleber HD (1986b). Chronic naltrexone effect on cortisol. NIDA Res Monogr 67: 362-365.
35. Krahn DD, Gosnell BA, Grace M, Levine AS (1986). CRF antagonist partially reverses CRF- and stress-induced effects on feeding. Brain Res Bull 17: 285-289.
36. Kreek MJ (1972). Medical safety, side effects and toxicity of methadone. Proceedings of the Fourth National Conference on Methadone Treatment. pp 171-174.
37. Kreek MJ (1973a). Medical safety and side effects of methadone in tolerant individuals. JAMA 223: 665-668.
38. Kreek MJ (1973b). Plasma and urine levels of methadone: comparison following four medication forms used in chronic maintenance treatment. NY State J Med 73: 2773-2777.
39. Kreek MJ (1978). Medical complications in methadone patients. Ann NY AcadSci 311: 110-134.
40. Kreek MJ (1996). Opiates, opioids and addiction. Mol Psychiatry 1: 232-254.
41. Kreek MJ, Hachey DL, Klein PD (1979). Stereoselective disposition of methadone in man. Life Sci 24: 925-932.
42. Kreek MJ, Koob GF (1998). Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 51: 23-47.
43. Kreek MJ, Ragunath J, Plevy S, Hamer D, Schneider B, Hartman N (1984). ACTH, cortisol and beta-endorphin response to metyr-apone testing during chronic methadone maintenance treatment in humans. Neuropeptides5: 277-278.
44. Kreek MJ, Wardlaw SL, Hartman N, Raghunath J, Friedman J, Schneider B et al (1983). Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sci 33(Suppl 1): 409-411.
45. Ladd CO, Owens MJ, Nemeroff CB (1996). Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology 137: 1212-1218.
46. LaForge KS, Kreek MJ (2000). Genetic contributions to protection from, or vulnerability to, addictive diseases. NIDA Res Monogr 180: 48.
47. LaForge KS, Yuferov V, Kreek MJ (2000). Opioid receptor and peptide gene polymorphisms: potential implications for addic-tions. Eur J Pharmacol 410: 249-268.
48. Le AD, Harding S, Juzytsch W, Watchus J, Shalev U, Shaham Y (2000). The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psycho-pharmacology (Berl) 150: 317-324.
49. Lee S, Smith GW, Vale W, Lee KF, Rivier C (2001). Mice that lack corticotropin-releasing factor (CRF) receptors type 1 show a blunted ACTH response to acute alcohol despite up-regulated constitutive hypothalamic CRF gene expression. Alcohol Clin Exp Res 25: 427-433.
50. Lu L, Ceng X, Huang M (2000). Corticotropin-releasing factor receptor type I mediates stress-induced relapse to opiate dependence in rats. Neuroreport 11: 2373-2378.
51. Lu L, Liu D, Ceng X (2001). Corticotropin-releasing factor receptor type 1 mediates stress-induced relapse to cocaine-conditioned place preference in rats. Eur J Pharmacol 415: 203-208.
52. Mantsch JR, Goeders NE (1999). Ketoconazole blocks the stress-induced reinstatement of cocaine-seeking behavior in rats: relationship to the discriminative stimulus effects of cocaine. Psychopharmacology (Berl) 142: 399-407.
53. Martins JM, Kastin AJ, Banks WA (1996).Unidirectional specific and modulated brain to blood transport of corticotropin-releasing hormone. Neuroendocrinology 63: 338-348.
54. Mendelson JH, Mello NK, Cristofaro P, Skupny A, Ellingboe J (1986). Use of naltrexone as a provocative test for hypothalamic-pituitary hormone function. PharmacolBiochemBehav 24: 309-313.
55. Mendelson JH, Sholar M, Mello NK, Teoh SK, Sholar JW (1998). Cocaine tolerance: behavioral, cardiovascular, and neuro-endocrine function in men. Neuropsychopharmacology 18: 263-271.
56. Muller OA, Hartwimmer J, Hauer A, Kaliebe T, Schopohl J, Stalla GK et al (1986). Corticotropin-releasing factor (CRF): stimulation in normal controls and in patients with Cushing’s syndrome. Psychoneuroendocrinology11: 49-60.
57. Nikolarakis K, Pfeiffer A, Stalla GK, Herz A (1987). The role of CRF in the release of ACTH by opiate agonists and antagonists in rats. Brain Res 421: 373-376.
58. O’Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002). Naltrexone decreases craving and alcohol self-adminis-tration in alcohol-dependent subjects and activates the hypotha-lamo-pituitary-adrenocortical axis. Psychopharmacology 160: 19-29.
59. Orth DN, Jackson RV, DeCherney GS, DeBold CR, Alexander AN, Island DP et al (1983).Effect of synthetic ovine corticotropin-releasing factor dose response of plasma adrenocorticotropin and cortisol. J Clin Invest 71: 587-595.
60. Plotsky PM, Meaney MJ (1993). Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats. Brain Res Mol Brain Res18: 195-200.
61. Radulovic J, Ruhmann A, Liepold T, Spiess J (1999). Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci 19: 5016-5025.
62. Richter RM, Pich EM, Koob GF, Weiss F (1995). Sensitization of cocaine-stimulated increase in extracellular levels of corticotro-pin-releasing factor from the rat amygdala after repeated administration as determined by intracranial microdialysis. NeurosciLett 187: 169-172.
63. Richter RM, Weiss F (1999). In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse 32: 254-261.
64. Sander T, Gscheidel N, Wendel B, Samochowiec J, Smolka M, Rommelspacher H et al (1998). Human mu-opioid receptor variation and alcohol dependence. Alcohol ClinExp Res 22: 2108-2110.
65. Saphier PW, Faria M, Grossman A, Coy DH, Besser GM, Hodson B et al (1992). A comparison of the clearance of ovine and human corticotrophin-releasing hormone (CRH) in man and sheep: a possible role for CRH-binding protein. J Endocrinol 133: 487-495.
66. Sarnyai Z, Shaham Y, Heinrichs SC (2001).The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 53: 209-243.
67. Schluger JH, Borg L, Ho A, Kreek MJ (2001). Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction. Neuro-psychopharmacology 24: 568-575.
68. Schluger JH, Ho A, Borg L, Porter M, Maniar S, Gunduz M et al (1998). Nalmefene causes greater hypothalamic-pituitary-adre-nal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol ClinExp Res 22: 1430-1436.
69. Schuckit MA, Edenberg HJ, Kalmijn J, Flury L, Smith TL, Reich T et al (2001). A genome-wide search for genes that relate to a low level of response to alcohol. Alcohol ClinExp Res 25: 323-329.
70. Schurmeyer TH, Avgerinos PC, Gold PW, Gallucci WT, Tomai TP, Cutler Jr GB et al (1984). Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion. J Clin EndocrinolMetab 59: 1103-1108.
71. Shaham Y, Erb S, Leung S, Buczek Y, Stewart J (1998). CP-154, 526, a selective, non-peptide antagonist of the corticotropin-releasing factor 1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology (Berl) 137: 184-190.
72. Shaham Y, Funk D, Erb S, Brown TJ, Walker CD, Stewart J (1997).Corticotropin-releasing factor, but not corticosterone, is in-volved in stress-induced relapse to heroin-seeking in rats. J Neurosci 17: 2605-2614.
73. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH et al (1998). Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20: 1093-1102.
74. Stimmel B, Kreek MJ (1975). Dependence, tolerance and with-drawal. In: Stimmel B (ed). Heroin Dependency: Medical, Economic and Social Aspects. Stratton Intercontinental Medical Book Corp.: New York. pp 88-97.
75. Sutton RE, Koob GF, Le Moal M, Rivier J, Vale W (1982). Corticotropin releasing factor produces behavioural activation in rats. Nature 297: 331-333.
76. Szeto CY, Tang NL, Lee DT, Stadlin A (2001). Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts. Neuroreport 12: 1103-1106.
77. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK et al (1998). Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19: 162-166.
78. Vale W, Spiess J, Rivier C, Rivier J (1981). Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213: 1394-1397.
79. Volavka J, Bauman J, Pevnick J, Reker D, James B, Cho D (1980). Short-term hormonal effects of naloxone in man. Psychoneur-oendocrinology 5: 225-234.
80. Volavka J, Cho D, Mallya A, Bauman J (1979). Naloxone increases ACTH and cortisol levels in man. N Engl J Med 300: 1056-1057.
81. vonBardeleben U, Heuser I, Holsboer F (1989). Human CRH stimulation response during acute withdrawal and after medium-term abstention from alcohol abuse. Psychoneuroendocri-nology 14: 441-449.
82. Waltman C, McCaul ME, Wand GS (1994).Adrenocorticotropin responses following administration of ethanol and ovine corticotropin-releasing hormone in the sons of alcoholics and control subjects. Alcohol ClinExp Res18: 826-830.
83. Wand GS, Mangold D, El Deiry S, McCaul ME, Hoover D (1998). Family history of alcoholism and hypothalamic opioidergic activity. Arch Gen Psychiatry 55: 1114-1119.
84. Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S et al (2002). The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26: 106-114.
85. Weninger SC, Dunn AJ, Muglia LJ, Dikkes P, Miczek KA, Swiergiel AH et al (1999). Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc NatlAcadSci USA 96: 8283-8288.
86. Zhou Y, Franck J, Spangler R, Maggos CE, Ho A, Kreek MJ (2000). Reduced hypothalamic POMC and anterior pituitary CRF1 receptor mRNA levels after acute, but not chronic, daily ‘binge’ intragastric alcohol administration. Alcohol ClinExp Res 24: 1575-1582.
87. Zhou Y, Spangler R, LaForge KS, Maggos CE, Ho A, Kreek MJ (1996a). Corticotropin-releasing factor and type 1 corticotro-pin-releasing factor receptor messenger RNAs in rat brain and pituitary during ‘binge’-pattern cocaine administration and chronic withdrawal. J PharmacolExpTher 279: 351-358.
88. Zhou Y, Spangler R, Maggos CE, LaForge KS, Ho A, Kreek MJ (1996b). Steady-state methadone in rats does not change mRNA levels of corticotropin-releasing factor, its pituitary receptor or proopiomelanocortin. Eur J Pharmacol 315: 31-35.
89. Zhou Y, Spangler R, Maggos CE, Wang XM, Han JS, Ho A et al (1999). Hypothalamic-pituitary-adrenal activity and pro-opio-melanocortin mRNA levels in the hypothalamus and pituitary of the rat are differentially modulated by acute intermittent morphine with or without water restriction stress. J Endocrinol 163: 261-267.
90. Zobel AW, Yassouridis A, Frieboes RM, Holsboer F (1999). Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry 156: 949-951.